Deutsche Bank Downgrades Akorn (AKRX) to Hold
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Deutsche Bank downgraded Akorn (NASDAQ: AKRX) from Buy to Hold with a price target of $33. Analyst Gregg Gilbert said launches will be key in the second half of the year.
"While we see upside based on potential approvals and deals over the next year, this upside potential is somewhat balanced by the increasing competitive intensity in the US generic space. AKRX’s interesting and diverse portfolio of specialized dosage forms has enabled the company to weather rocky times better than some other small/medium-sized US generic players. But with the stock having made a nice recovery from its 3/21 bottom, which was in large part tied to the SEC filing delays and de-listing risk, we are less comfortable recommending the stock at this price on the premise that new products and deals will significantly overwhelm the effects of an increasingly competitive market," said Gilbert.
"We continue to believe that management is shareholder friendly and is doing the right things to position AKRX for long-term value creation. An underlevered balance sheet creates some optionality as well. Many investors (and we) see AKRX as an attractive asset in an ever-consolidating environment, although much of the generic M&A in recent times has been done in the smaller size range (vs. AKRX’s enterprise value of ~$4.6bn)," added the analyst.
Shares of Akorn closed at $31.24 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Herbalife (HLF) Provides Q4, FY17 Guidance in Memorandum for $1.325B Credit Facility; Lowers FY17 Sales Guidance
- Union Pacific (UNP) PT Raised to $120 at Aegis Capital Following Solid 4Q
- JPMorgan Downgrades Endo International plc (ENDP) to Neutral
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, Downgrades
Related EntitiesDeutsche Bank
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!